139 related articles for article (PubMed ID: 21870922)
21. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.
Müller DJ; Zai CC; Sicard M; Remington E; Souza RP; Tiwari AK; Hwang R; Likhodi O; Shaikh S; Freeman N; Arenovich T; Heinz A; Meltzer HY; Lieberman JA; Kennedy JL
Pharmacogenomics J; 2012 Apr; 12(2):156-64. PubMed ID: 20714340
[TBL] [Abstract][Full Text] [Related]
22. Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder.
Reutfors J; Brandt L; Stephansson O; Kieler H; Andersen M; Bodén R
J Clin Psychopharmacol; 2013 Dec; 33(6):759-65. PubMed ID: 24126686
[TBL] [Abstract][Full Text] [Related]
23. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics.
Nakonezny PA; Byerly MJ
Schizophr Res; 2006 Feb; 82(1):107-14. PubMed ID: 16376522
[TBL] [Abstract][Full Text] [Related]
24. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
[TBL] [Abstract][Full Text] [Related]
25. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia.
Sumiyoshi T; Jayathilake K; Meltzer HY
Schizophr Res; 2003 Jan; 59(1):7-16. PubMed ID: 12413636
[TBL] [Abstract][Full Text] [Related]
26. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
Sharma RP; Janicak PG; Bissette G; Nemeroff CB
Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
[TBL] [Abstract][Full Text] [Related]
27. Clozapine and olanzapine, but not haloperidol, reverse cold-induced and lipopolysaccharide-induced cutaneous vasoconstriction.
Blessing WW
Psychopharmacology (Berl); 2004 Oct; 175(4):487-93. PubMed ID: 15083260
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of quality of life for patients with schizophrenic and schizoaffective disorders related to the use of antipsychotic therapy.
Golubovic B; Misic-Pavkov G; Gajic Z; Ivanovic-Kovacevic S
Med Arh; 2010; 64(1):37-40. PubMed ID: 20422824
[TBL] [Abstract][Full Text] [Related]
29. Acute Blood Pressure Changes Associated With Antipsychotic Administration to Psychiatric Inpatients.
Parks KA; Parks CG; Yost JP; Bennett JI; Onwuameze OE
Prim Care Companion CNS Disord; 2018 Jul; 20(4):. PubMed ID: 30036457
[TBL] [Abstract][Full Text] [Related]
30. The role of atypical antipsychotic agents in the treatment of schizophrenia and schizoaffective disorders in the elderly.
Madhusoodanan S; Sinha A; Sajatovic M; Gupta S; Brenner R
Curr Drug Saf; 2006 Aug; 1(3):227-41. PubMed ID: 18690933
[TBL] [Abstract][Full Text] [Related]
31. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder.
Dunayevich E; Ascher-Svanum H; Zhao F; Jacobson JG; Phillips GA; Dellva MA; Green AI
J Clin Psychiatry; 2007 Aug; 68(8):1163-71. PubMed ID: 17854239
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacological treatment of schizoaffective disorder, schizophreniform disorder and brief psychotic disorder].
Rebok F
Vertex; 2012; 23(104):287-98. PubMed ID: 23170301
[TBL] [Abstract][Full Text] [Related]
33. Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program.
Meyer PS; Bond GR; Tunis SL; McCoy ML
J Clin Psychiatry; 2002 Feb; 63(2):108-16. PubMed ID: 11874210
[TBL] [Abstract][Full Text] [Related]
34. Impact of Psychoeducation on Knowledge of and Attitude Toward Medications in Clients With Schizophrenia and Schizoaffective Disorders.
Choe K; Sung BJ; Kang Y; Yoo SY
Perspect Psychiatr Care; 2016 Apr; 52(2):113-9. PubMed ID: 25640073
[TBL] [Abstract][Full Text] [Related]
35. Sexual dysfunction in patients with schizophrenia and schizoaffective disorder and its association with adherence to antipsychotic medication.
Souaiby L; Kazour F; Zoghbi M; Bou Khalil R; Richa S
J Ment Health; 2020 Dec; 29(6):623-630. PubMed ID: 30862199
[No Abstract] [Full Text] [Related]
36. Pharmacologic treatment of schizoaffective disorder.
Keck PE; McElroy SL; Strakowski SM; West SA
Psychopharmacology (Berl); 1994 May; 114(4):529-38. PubMed ID: 7855214
[TBL] [Abstract][Full Text] [Related]
37. Decision-making Capacity for Treatment of Psychotic Patients on Long Acting Injectable Antipsychotic Treatment.
Nystazaki M; Pikouli K; Tsapakis EM; Karanikola M; Ploumpidis D; Alevizopoulos G
Arch Psychiatr Nurs; 2018 Apr; 32(2):300-304. PubMed ID: 29579528
[TBL] [Abstract][Full Text] [Related]
38. Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study.
Chen HK; Hsieh CJ
Schizophr Res; 2018 May; 195():237-244. PubMed ID: 29107449
[TBL] [Abstract][Full Text] [Related]
39. CSF thyrotropin-releasing hormone concentrations differ in patients with schizoaffective disorder from patients with schizophrenia or mood disorders.
Sharma RP; Martis B; Rosen C; Jonalagadda J; Nemeroff CB; Bissette G
J Psychiatr Res; 2001; 35(5):287-91. PubMed ID: 11591431
[TBL] [Abstract][Full Text] [Related]
40. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.
Fernandes BS; Steiner J; Bernstein HG; Dodd S; Pasco JA; Dean OM; Nardin P; Gonçalves CA; Berk M
Mol Psychiatry; 2016 Apr; 21(4):554-64. PubMed ID: 26169974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
